Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Argus Health
Daiichi Sankyo
Johnson and Johnson
Federal Trade Commission

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,592,434

« Back to Dashboard

Which drugs does patent 8,592,434 protect, and when does it expire?

Patent 8,592,434 protects SITAVIG and is included in one NDA.

This patent has six patent family members in five countries.

Summary for Patent: 8,592,434

Title:Mucoadhesive buccal tablets for the treatment of orofacial herpes
Abstract: The present invention relates to the treatment or prevention of mucocutaneous herpes simplex virus diseases using prolonged release mucoadhesive buccal tablets comprising an acyclic guanosine antiviral agent. These tablets are particularly suitable for the treatment or prevention of orofacial herpes.
Inventor(s): Attali; Pierre (Vincennes, FR), Costantini; Dominique (Paris, FR), Lemarchand; Caroline (Paris, FR)
Assignee: BioAlliance Pharma SA (Paris, FR)
Application Number:12/634,225
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Epi HlthSITAVIGacyclovirTABLET;BUCCAL203791-001Apr 12, 2013RXYesYes► Subscribe► Subscribe► SubscribeYTREATMENT OF HERPES LABIALIS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,592,434

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2782779► Subscribe
China102652016► Subscribe
European Patent Office2335690► Subscribe
European Patent Office2509586► Subscribe
Japan2013513575► Subscribe
World Intellectual Property Organization (WIPO)2011070125► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Federal Trade Commission
Cantor Fitzgerald
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: